5,306 results match your criteria Schizoaffective Disorder


The characterization of social anhedonia and its correlates in schizophrenia and schizoaffective patients.

Psychiatry Res 2018 Dec 4;270:922-928. Epub 2018 Nov 4.

Department of Psychology, University of Wisconsin-Madison, 1202 W. Johnson Street, Madison, WI 53706, United States. Electronic address:

Although social hedonic capacity is often assessed in clinical settings, its operational definitions have not been evaluated for concurrent validity. One hundred and twenty-five patients with schizophrenia and schizoaffective disorder were classified according to their self-reported social hedonic functioning into three groups on the basis of their total scores on the Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS). Participants were assessed before discharge using questionnaires and psychiatric rating scales. Read More

View Article
December 2018

Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications.

J Clin Psychiatry 2018 Nov 27;80(1). Epub 2018 Nov 27.

Department of Psychiatry and Health Behaviors, Augusta University Health, Augusta, Georgia, USA.

Objective: To investigate subgroup responses to long-acting injectable (LAI) medications haloperidol decanoate (HD) and paliperidone palmitate (PP) in a randomized controlled trial that found no difference between the treatments on the primary outcome of efficacy failure.

Methods: A Comparison of Long-Acting Injectable Medications for Schizophrenia (ACLAIMS) enrolled 311 participants from March 2011 to July 2013 meeting DSM-IV-TR criteria for diagnoses of schizophrenia or schizoaffective disorder at risk of relapse due to medication nonadherence or substance abuse. Participants were randomly assigned to double-blinded treatment with HD or PP and followed for up to 2 years. Read More

View Article
November 2018
1 Read

First-generation second-generation long-acting injectable antipsychotic drugs and time to relapse.

Ther Adv Psychopharmacol 2018 Dec 25;8(12):333-336. Epub 2018 Sep 25.

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Background: The development of long-acting injectable formulations (LAIs) of second-generation antipsychotic drugs (SGAs) has been suggested as having advantage over first-generation antipsychotic (FGA) LAIs. In this study, we investigated the hypothesis that there was a longer time to relapse in patients with schizophrenia started on SGA LAI FGA LAI.

Methods: Patients with a diagnosis of schizophrenia or schizoaffective disorder who were started on an SGA LAI while on an inpatient ward were identified through searching of the anonymised historical medical records at the South London and Maudsley NHS Foundation Trust. Read More

View Article
December 2018
1 Read

Hippocampal volume and vasculature before and after exercise in treatment-resistant schizophrenia.

Schizophr Res 2018 Dec 29;202:158-165. Epub 2018 Jun 29.

Department of Radiology, University of British Columbia, Canada. Electronic address:

Background: Schizophrenia is associated with poor cognitive function and elevated cardiometabolic disease risk. These health concerns may exacerbate neurocognitive dysfunction associated with hippocampal abnormalities, particularly hippocampal volume reductions. Regular exercise is thought to improve symptom severity, reduce depression, and improve cognition in schizophrenia, and may trigger exercise-mediated hippocampal growth. Read More

View Article
December 2018

Psychiatric comorbidy in Ullrich-Turner syndrome.

Fortschr Neurol Psychiatr 2018 Dec 11. Epub 2018 Dec 11.

Ruhr-Universität Bochum, Psychiatrie.

Objective: Ullrich-Turner Syndrome (UTS; Turner Syndrome (TS)) is a X-chromosomal disorder, which is characterized by a variety and heterogenous clinical conditions. Although it is not typically associated with neuropsychiatric disorders, several case reports describe concomitant TS and neuropsychiatric abnormalities that may represent a pathogenetic link.

Methods: Based on the case representation of woman with TS and co-occurrent schizoaffective disorder we discuss possible relationships and current literature. Read More

View Article
December 2018
3 Reads

PET neuroimaging reveals histone deacetylase dysregulation in schizophrenia.

J Clin Invest 2018 Dec 10. Epub 2018 Dec 10.

Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.

Background: Patients with schizophrenia (SCZ) experience chronic cognitive deficits. Histone deacetylases (HDACs) are enzymes that regulate cognitive circuitry; however, the role of HDACs in cognitive disorders, including SCZ, remains unknown in humans. We previously determined that HDAC2 mRNA levels were lower in dorsolateral prefrontal cortex (DLPFC) tissue from donors with SCZ compared with controls. Read More

View Article
December 2018

An investigation into the relationship between clozapine treatment and cognitive performance in patients with treatment resistant schizophrenia.

Schizophr Res 2018 Dec 5. Epub 2018 Dec 5.

Rehabilitation Academic Clinical Unit, Metro South Mental Health and Addiction Services, Brisbane, Qld, Australia; School of Medicine, The University of Queensland, Brisbane, Qld, Australia.

View Article
December 2018

A Naturalistic Study of Racial Disparities in Diagnoses at an Outpatient Behavioral Health Clinic.

Psychiatr Serv 2018 Dec 10:appips201800223. Epub 2018 Dec 10.

Rutgers University Behavioral Health Care, Piscataway, New Jersey (Gara, Minsky, Silverstein, Miskimen); Department of Psychiatry, Robert Wood Johnson Medical School, Rutgers University, Piscataway, New Jersey (Gara, Silverstein, Miskimen); Department of Psychiatry, Dell Medical School, University of Texas at Austin (Strakowski).

Objective:: The authors examined electronic medical record (EMR) outpatient data to determine whether African Americans with schizophrenia or schizoaffective disorder were more likely than non-Latino whites to screen positive for major depression.

Methods:: EMR data for 1,657 patients at Rutgers University Behavioral Health Care certified community outpatient clinics were deidentified and accrued for 9 months starting July 1, 2017. A Fisher's exact test was used to compare differences in the proportion of patients with positive screens for major depression (cutoff score of ≥15 on the nine-item Patient Health Questionnaire) among African-American and non-Latino white patients diagnosed as having schizophrenia or schizoaffective disorder. Read More

View Article
December 2018

Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia.

Neuropsychopharmacology 2018 Nov 22. Epub 2018 Nov 22.

Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, ON, Canada.

Although some studies have suggested that relapse may be associated with antipsychotic treatment resistance in schizophrenia, the number and quality of studies is limited. The current analysis included patients with a diagnosis of first-episode schizophrenia or schizoaffective disorder who met the following criteria: (1) referral to the First-Episode Psychosis Program between 2003 and 2013; (2) treatment with an oral second-generation antipsychotic according to a standardized treatment algorithm; (3) positive symptom remission; (4) subsequent relapse (i.e. Read More

View Article
November 2018
3 Reads

Risk of schizophrenia, schizoaffective, and bipolar disorders by migrant status, region of origin, and age-at-migration: a national cohort study of 1.8 million people.

Psychol Med 2018 Dec 5:1-10. Epub 2018 Dec 5.

Division of Psychiatry,UCL,London,UK.

Background: We assessed whether the risk of various psychotic disorders and non-psychotic bipolar disorder (including mania) varied by migrant status, a region of origin, or age-at-migration, hypothesizing that risk would only be elevated for psychotic disorders.

Methods: We established a prospective cohort of 1 796 257 Swedish residents born between 1982 and 1996, followed from their 15th birthday, or immigration to Sweden after age 15, until diagnosis, emigration, death, or end of 2011. Cox proportional hazards models were used to model hazard ratios by migration-related factors, adjusted for covariates. Read More

View Article
December 2018
5 Reads

Autoimmune encephalitis with psychosis: Warning signs, step-by-step diagnostics and treatment.

World J Biol Psychiatry 2018 Dec 4:1-25. Epub 2018 Dec 4.

e Department of Psychiatry and Psychotherapy , Ludwig-Maximilians-University Munich , Munich , Germany.

Objectives: Despite intensive research, schizophrenia and schizoaffective disorders continue to be theoretical constructs that describe clinical syndromes and no pathophysiologically defined diseases. Moreover, there are no clear biomarkers at hand. Therefore, these diagnoses are still set up based on clinical ICD-10 / DSM-5 criteria and the exclusion of alcohol- / drug-associated, systemic or other brain organic causes. Read More

View Article
December 2018
2 Reads

Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT.

Health Technol Assess 2018 Nov;22(65):1-160

Leicester Diabetes Centre, University Hospitals of Leicester, Leicester, UK.

Background: Obesity is twice as common in people with schizophrenia as in the general population. The National Institute for Health and Care Excellence guidance recommends that people with psychosis or schizophrenia, especially those taking antipsychotics, be offered a healthy eating and physical activity programme by their mental health care provider. There is insufficient evidence to inform how these lifestyle services should be commissioned. Read More

View Article
November 2018
1 Read

Factors associated with visits to general practitioners in patients with schizophrenia in Malaga.

BMC Fam Pract 2018 Nov 28;19(1):180. Epub 2018 Nov 28.

Andalusian Group of Psychosocial Research (GAP), Malaga, Spain.

Background: Patients with psychiatric disorders have more physical problems than other patients, so their follow-up by the general practitioner is particularly important for them.

Methods: We aimed to elaborate a multilevel explanatory model of general practitioner (GP) visits made by patients with schizophrenia and related disorders (SRD). An observational, cross-sectional study was conducted from January 1, 2008 to July 1, 2011, in the area of the Clinical Management Unit of Mental Health (CMU-MH) of the Regional Hospital of Malaga (Spain). Read More

View Article
November 2018
4 Reads

Why Do People With Schizophrenia Exercise? A Mixed Methods Analysis Among Community Dwelling Regular Exercisers.

Front Psychiatry 2018 13;9:596. Epub 2018 Nov 13.

Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA, United States.

Individuals with schizophrenia have reduced rates of physical activity, yet substantial proportions do engage in independent and regular exercise. Previous studies have shown improvement in symptoms and cognitive function in response to supervised exercise programs in people with schizophrenia. There is little data on motivations of individuals who exercise independently, or their chosen type, duration, or setting of exercise. Read More

View Article
November 2018
5 Reads

Patterns of Management of Patients With Dual Disorder (Psychosis) in Italy: A Survey of Psychiatrists and Other Physicians Focusing on Clinical Practice.

Front Psychiatry 2018 13;9:575. Epub 2018 Nov 13.

Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.

Patients with severe psychotic disorders such as schizophrenia, schizoaffective, and bipolar disorders frequently suffer from concomitant substance use disorders (SUDs)-Dual Disorder (DD) patients. In order to better understand current practices for management of patients with psychotic episodes and concomitant SUD in Italy, we carried out a survey of psychiatrists on current routine practice among prescribers. These aspects can help to identify at-risk patients, improve current prescribing practices, and favor early intervention. Read More

View Article
November 2018
1 Read

Contributions of olfactory and neuropsychological assessment to the diagnosis of first-episode schizophrenia.

Neuropsychology 2018 Nov 26. Epub 2018 Nov 26.

Department of Psychiatry and Behavioral Sciences.

Objective: First-episode schizophrenia and schizoaffective patients (SZ+) show olfactory impairments, but how these relate to cognitive dysfunction remains unclear. We examined the relationship between cognitive and olfactory dysfunction in SZ+ and the clinical utility of these measures in the assessment of SZ+ patients.

Method: First-episode SZ+ patients (n = 63) and controls (n = 63) were administered tests of odor identification and discrimination in addition to measures of manual dexterity, processing speed, attention and working memory, executive functioning, ideational fluency, and memory. Read More

View Article
November 2018
5 Reads

Metacognitive Reflection and Insight Therapy (MERIT) Among People With Schizophrenia: Lessons From Two Case Studies.

Am J Psychother 2018 Nov 26:appipsychotherapy20180037. Epub 2018 Nov 26.

Department of Psychology, Bar-Ilan University, Ramat-Gan, Israel (Arnon-Ribenfeld, Bloom, Atzil-Slonim, Peri, Hasson-Ohayon); Department of Clinical Psychology, University of Amsterdam, Amsterdam (de Jong).

People with schizophrenia spectrum disorder face a major challenge in the ability to reflect on their own and others' mental activities and about specific psychological problems in their lives. These deficits are associated with increased symptoms and lower functioning. Specific interventions have been designed to enhance these abilities, one of which is metacognitive reflection and insight therapy (MERIT). Read More

View Article
November 2018
2 Reads

Clozapine-related Sudden Pericarditis in a Patient Taking Long Acting Aripiprazole and Valproate: A Case Report.

Clin Psychopharmacol Neurosci 2018 Nov;16(4):505-507

Department of Neurosciences and Imaging, University "G. d'Annunzio", Chieti, Italy.

Clozapine may be associated with cardiovascular adverse effects including QTc prolongation and, more rarely, with myocarditis and pericarditis. Although rare, these latter cardiovascular adverse effects may be life-threatening and must be immediately recognized and treated. Several cases of clozapine related-pericarditis have been described and often it has a subtle and insidious onset with symptoms that may be often misdiagnosed with psychiatric manifestations (e. Read More

View Article
November 2018
3 Reads

Self-assessment of negative symptoms - Critical appraisal of the motivation and pleasure - Self-report's (MAP-SR) validity and reliability.

Compr Psychiatry 2019 Jan 30;88:22-28. Epub 2018 Oct 30.

Department of Psychiatry and Psychotherapy, University of Tübingen, Calwerstraße 14, 72076 Tübingen, Germany. Electronic address:

Objective: The negative symptom domain remains a major challenge concerning treatment. A valid self-report measure could assist clinicians and researchers in identifying patients with a relevant subjective burden. The Motivation and Pleasure - Self Report (MAP-SR) derives from the CAINS and is supposed to reflect the "amotivation" factor of negative symptoms. Read More

View Article
January 2019
3 Reads

Hypomania Symptoms Across Psychiatric Disorders: Screening Use of the Hypomania Check-List 32 at Admission to an Outpatient Psychiatry Clinic.

Front Psychiatry 2018 7;9:527. Epub 2018 Nov 7.

Champalimaud Clinical Centre, Champalimaud Centre for the Unknown, Lisbon, Portugal.

Hypomania symptoms are best described as a continuum, ranging beyond Bipolar Spectrum Disorders (BSD). Other nosological entities, such as major depressive disorder, schizoaffective disorder, or borderline personality disorder, may also share symptoms with BSD, raising challenges for differential diagnosis. While the Hypomania Checklist-32 is one of the most widely used tools for screening hypomania, there is limited evidence describing its use in a real-world outpatient psychiatric clinical setting. Read More

View Article
November 2018
5 Reads

Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder.

CNS Spectr 2018 Nov 21:1-17. Epub 2018 Nov 21.

10Zucker Hillside Hospital,Psychiatry Research,Northwell Health,Glen Oaks,New York.

Objective: Our aim was to summarize the efficacy and safety of atomoxetine, amphetamines, and methylphenidate in schizophrenia.

Methods: We undertook a systematic review, searching PubMed/Scopus/Clinicaltrials.gov for double-blind, randomized, placebo-controlled studies of psychostimulants or atomoxetine in schizophrenia published up to 1 January 2017. Read More

View Article
November 2018
2 Reads
2.710 Impact Factor

The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial.

Schizophr Res 2018 Nov 16. Epub 2018 Nov 16.

Department of Psychiatry, University of Illinois, Chicago, IL 60607, USA.

Background: Studies have hypothesized that immunological abnormalities might contribute to schizophrenia, and basic science studies, as well as several clinical trials suggest that minocycline could be efficacious in ameliorating both positive and negative symptoms of schizophrenia. In this study we examined the effect of minocycline on schizophrenia in a large randomized controlled trial.

Methods: We performed a 16-week, multi-center, double-blind, randomized, placebo-controlled study on 200 subjects with schizophrenia or schizoaffective disorder randomized to receive either minocycline (200 mg/day, n = 100), or placebo (n = 100) as an add-on to anti-psychotic treatment. Read More

View Article
November 2018

Long-Term Severe Mental Disorders Preceding Behavioral Variant Frontotemporal Dementia: Frequency and Clinical Correlates in an Outpatient Sample.

J Alzheimers Dis 2018 Nov 15. Epub 2018 Nov 15.

Grupo de Pesquisa em Neurologia Cognitiva e do Comportamento, Departamento de Clínica Médica, Faculdade de Medicina da Universidade Federal de Minas Gerais, Belo Horizonte (MG), Brazil.

Background: The behavioral variant frontotemporal dementia (bvFTD) shares some clinical features with severe mental disorders, such as bipolar affective disorder (BAD), schizophrenia (SCZ), and schizoaffective disorder (SZA), and at least for a small subgroup of patients, these conditions may share similar pathological genetic mutations.

Objectives: To investigate the frequency of a past medical history satisfying diagnostic criteria for BAD, SCZ, and SZA in a bvFTD outpatient sample, and to compare the clinical profile of patients with and without a positive history.

Methods: Cross-sectional study in which participants were consecutively selected after receiving a diagnosis of probable bvFTD and had a caregiver interviewed with SCID-I. Read More

View Article
November 2018
8 Reads

A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone.

Expert Rev Clin Pharmacol 2018 Dec 4;11(12):1237-1253. Epub 2018 Dec 4.

e University of Kentucky Mental Health Research Center at Eastern State Hospital , Lexington , KY , USA.

Introduction: This is a combined analysis of therapeutic drug monitoring (TDM) studies of long-acting injectable paliperidone formulations: monthly (PP1M) and three-month (PP3M) injections. Areas covered: Fourteen PP1M articles and one PP3M article were identified. Using the paliperidone concentration/dose (C/D) ratio as a measure of clearance provided a weighted mean of 7. Read More

View Article
December 2018
2 Reads

Psoas Abscess as a Differential Diagnosis of Neuroleptic Malignant Syndrome in a Schizoaffective Disorder Patient With Catatonic Symptoms.

Prim Care Companion CNS Disord 2018 Nov 1;20(6). Epub 2018 Nov 1.

Psychiatry Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.

View Article
November 2018
8 Reads

Self-reported treatment adherence among psychiatric in- and outpatients.

Nord J Psychiatry 2018 Nov 16:1-8. Epub 2018 Nov 16.

d Department of Psychiatry , Institute of Clinical Medicine , Helsinki , Finland.

Background: Poor adherence to psychiatric treatment is a common clinical problem, leading to unfavourable treatment outcome and increased healthcare costs.

Aim: The aim of this study was to investigate the self-reported adherence and attitudes to outpatient visits and pharmacotherapy in specialized care psychiatric patients.

Methods: Within the Helsinki University Psychiatric Consortium (HUPC) pilot study, in- and outpatients with schizophrenia or schizoaffective disorder (SSA, n  =  113), bipolar disorder (BD, n  =  99), or depressive disorder (DD, n  =  188) were surveyed about their adherence and attitudes towards outpatient visits and pharmacotherapy. Read More

View Article
November 2018
4 Reads

Cognitive Behavioural Therapy for Psychosis: A Health Technology Assessment.

Authors:

Ont Health Technol Assess Ser 2018 24;18(5):1-141. Epub 2018 Oct 24.

Background: Cognitive behavioural therapy (CBT) for psychosis is a distinct type of psychotherapy that has been recommended together with antipsychotic drugs and comprehensive usual care in the management of schizophrenia, a complex mental health disorder associated with a high economic and societal burden. The objectives of this report were to assess the effectiveness, harms, cost-effectiveness, and lived experience of CBT for psychosis in improving outcomes for adults with a primary diagnosis of schizophrenia.

Methods: We performed literature searches on March 28 and April 5, 2017, and undertook a qualitative synthesis of systematic reviews of the clinical and economic literature comparing CBT for psychosis with any comparator interventions (e. Read More

View Article
October 2018
6 Reads

Individual-specific functional connectivity markers track dimensional and categorical features of psychotic illness.

Mol Psychiatry 2018 Nov 15. Epub 2018 Nov 15.

Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.

Neuroimaging studies of psychotic disorders have demonstrated abnormalities in structural and functional connectivity involving widespread brain networks. However, these group-level observations have failed to yield any biomarkers that can provide confirmatory evidence of a patient's current symptoms, predict future symptoms, or predict a treatment response. Lack of precision in both neuroanatomical and clinical boundaries have likely contributed to the inability of even well-powered studies to resolve these key relationships. Read More

View Article
November 2018
15 Reads

Does Schizoaffective Disorder explain the mental illnesses of Robert Schumann and Vincent Van Gogh?

Psychiatr Danub 2018 Nov;30(Suppl 7):559-562

Clare College Cambridge, University of Cambridge, Trinity Lane, Cambridge, CB2 1TL, UK,

The geniuses Robert Schumann and Vincent Van Gogh show striking similarities both in the longitudinal nature of the progression of their illnesses, and the symptoms they experienced. There have been physiological explanations posed for both men, including Meniere's disease, tertiary syphilis, acute intermittent porphyria, terpenoid and lead poisoning, intracranial masses, temporal lobe epilepsy and dementia caused by vascular hypertension. The evidence for these physiological explanations is assessed. Read More

View Article
November 2018
3 Reads

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study.

BMC Psychiatry 2018 Nov 14;18(1):365. Epub 2018 Nov 14.

Klinik für Psychiatrie und Psychotherapie, Zentrum für Psychosoziale Medizin, Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.

Background: In this study, the treatment of schizophrenia patients with aripiprazole once-monthly (AOM) was evaluated under real-life conditions in a naturalistic setting.

Methods: This multicenter, prospective, non-interventional study included 242 patients (age = 43.1 ± 15. Read More

View Article
November 2018
2 Reads

Effectiveness of Integrated Neurocognitive Therapy on Cognitive Impairment and Functional Outcome for Schizophrenia Outpatients.

Schizophr Res Treatment 2018 21;2018:2360697. Epub 2018 Oct 21.

Department of Public Health and Infection Disease, Sapienza University of Rome, Italy.

Cognitive impairment is highly prevalent in patients with schizophrenia and schizoaffective disorder. Many interventions have been developed to treat cognitive deficit, since it has a strong impact on functional outcome; however, there are no integrated interventions targeting multiple neuro- and social-cognitive domains with a particular focus on the generalization of the effects of therapy on the functional outcome. Recently, a group of experts has developed a cognitive remediation group therapy approach called Integrated Neurocognitive Therapy (INT), which includes exercises to improve the MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) neuro- and social-cognitive domains. Read More

View Article
October 2018
6 Reads

Vulnerable combinations of functional dopaminergic polymorphisms to late-onset treatment resistant schizophrenia.

PLoS One 2018 8;13(11):e0207133. Epub 2018 Nov 8.

Department of Psychiatry, Chiba University Graduate School of Medicine, Chuou-ku, Chiba, Chiba, Japan.

Background: A significant portion of patients with schizophrenia who respond to initial antipsychotic treatment acquire treatment resistance. One of the possible pathogeneses of treatment-resistant schizophrenia (TRS) is antipsychotic-induced dopamine supersensitivity psychosis (Ai-DSP). Patients with this disease progression might share some genetic vulnerabilities, and thus determining individuals with higher risks of developing Ai-DSP could contribute to preventing iatrogenic development of TRS. Read More

View Article
November 2018
3 Reads

Dual Use of a Patient Portal and Clinical Video Telehealth by Veterans with Mental Health Diagnoses: Retrospective, Cross-Sectional Analysis.

J Med Internet Res 2018 Nov 7;20(11):e11350. Epub 2018 Nov 7.

Pain Research, Informatics, Multimorbidities and Education Center, VA Connecticut Healthcare System, West Haven, CT, United States.

Background: Access to mental health care is challenging. The Veterans Health Administration (VHA) has been addressing these challenges through technological innovations including the implementation of Clinical Video Telehealth, two-way interactive and synchronous videoconferencing between a provider and a patient, and an electronic patient portal and personal health record, My HealtheVet.

Objective: This study aimed to describe early adoption and use of My HealtheVet and Clinical Video Telehealth among VHA users with mental health diagnoses. Read More

View Article
November 2018
2 Reads

Clozapine-induced myocarditis: Two case reports and review of clinical presentation and recognition.

Ment Health Clin 2018 Nov 1;8(6):303-308. Epub 2018 Nov 1.

Associate Chief, Clinical Pharmacy Programs and Mental Health Clinical Pharmacy Specialist, Pharmacy Department, South Texas Veterans Healthcare System, San Antonio, Texas; Assistant Clinical Professor, Pharmacotherapy Division, College of Pharmacy, The University of Texas at Austin, Austin, Texas.

Myocarditis is a potentially fatal cardiac disease marked by inflammation of the heart muscle. With a noted black-box warning, rates of clozapine-induced myocarditis are reportedly as high as 3%. Since the first case of clozapine-induced myocarditis was documented in 1994, more than 250 cases have been described in literature with an approximate 33% case-fatality rate. Read More

View Article
November 2018
7 Reads

-Phthalyl-l-Tryptophan (RG108), like Clozapine (CLO), Induces Chromatin Remodeling in Brains of Prenatally Stressed Mice.

Mol Pharmacol 2019 Jan 5;95(1):62-69. Epub 2018 Nov 5.

The Psychiatric Institute, Center for Alcohol Research in Epigenetics, Department of Psychiatry, College of Medicine, University of Illinois at Chicago, Chicago, Illinois

Schizophrenia (SZ), schizoaffective (SZA), and bipolar (BP) disorder are neurodevelopmental psychopathological conditions related, in part, to genetic load and, in part, to environmentally induced epigenetic dysregulation of chromatin structure and function in neocortical GABAergic, glutamatergic, and monoaminergic neurons. To test the above hypothesis, we targeted our scientific efforts on identifying whether the molecular epigenetic signature of postmortem brains of patients with SZ, SZA, and BP disorder are also present in the brains of adult mice born from dams prenatally restraint stressed (PRS) during gestation. The brains of PRS mice, which are similar to the brains of patients with SZ and BP disorder, show an ∼2-fold increased binding of DNMT1 to psychiatric candidate promoters (glutamic acid decarboxylase 67, Reelin, and brain-derived neurotrophic factor), leading to their hypermethylation, reduced expression, as well as the behavioral endophenotypes reminiscent of those observed in the above psychiatric disorders. Read More

View Article
January 2019
1 Read

Visuospatial and Sensory Integration Tasks in Patients With Schizophrenia or Schizoaffective Disorder: Relationship to Body Mass Index and Smoking.

Front Psychiatry 2018 16;9:473. Epub 2018 Oct 16.

Department of Psychiatry, Cooper Medical School, Rowan University, Camden, NJ, United States.

Neurological soft signs (NSSs) are highly prevalent among patients with schizophrenia, but their pathophysiological significance remains unclear. The present study employed perceptual-motor and visuospatial processing tests that have not yet been attempted in this patient population. Patients with schizophrenia or schizoaffective disorder ( = 42) and mentally healthy subjects ( = 10) were administered Copy Figure Test, Detection and Recognition of an Object Test and Road Map Test. Read More

View Article
October 2018
1 Read

Changes in insight over the first 24 months of treatment in schizophrenia spectrum disorders.

Schizophr Res 2018 Oct 29. Epub 2018 Oct 29.

Department of Psychiatry, Stellenbosch University, South Africa.

Background: While insight in schizophrenia improves with treatment, significant impairments often persist. The degree of persistence is not well characterised.

Aims: We assessed patient and clinician-rated changes in insight in acutely ill, minimally treated first-episode schizophrenia spectrum disorder patients over 24 months of standardised treatment with a depot antipsychotic. Read More

View Article
October 2018
2 Reads
3.923 Impact Factor

The WorkingWell Mobile Phone App for Individuals With Serious Mental Illnesses: Proof-of-Concept, Mixed-Methods Feasibility Study.

JMIR Ment Health 2018 Oct 25;5(4):e11383. Epub 2018 Oct 25.

Department of Psychiatry, The Geisel School of Medicine at Dartmouth, Lebanon, NH, United States.

Background: The disparities in employment for individuals with serious mental illnesses have been well documented, as have the benefits of work. Mobile technology can provide accessible in-the-moment support for these individuals. The WorkingWell mobile app was developed to meet the need for accessible follow-along supports for individuals with serious mental illnesses in the workplace. Read More

View Article
October 2018
6 Reads

Ondansetron - a promising adjunctive treatment for persistent schizophrenia.

J Psychopharmacol 2018 Nov 25;32(11):1204-1211. Epub 2018 Oct 25.

The Monash Alfred Psychiatry Research Centre, Monash University and The Alfred Hospital, Melbourne, VIC, Australia.

Background:: Ondansetron is a serotonin 3 receptor antagonist widely used to prevent nausea and vomiting in pregnancy and in patients receiving chemotherapy. There is growing evidence that adjunctive ondansetron treatment improves symptomatology associated with schizophrenia, particularly with respect to the positive, negative and cognitive symptoms. Further studies that are applicable to real world practice are required to assess the efficacy and effectiveness of this treatment, which could be readily and rapidly translated into clinical practice. Read More

View Article
November 2018
4 Reads

Patients' satisfaction with hospital health care: Identifying indicators for people with severe mental disorder.

Psychiatry Res 2018 Dec 10;270:503-509. Epub 2018 Oct 10.

National Insurance Institute in Israel, Haifa, Israel. Electronic address:

Background: Patients' perception of psychiatric healthcare is a critical indicator in measuring service quality. The aim of the study was to determine patient's level of satisfaction with the quality of health care delivered at the inpatient departments, and to identify the service quality factors that were important to patients.

Method: The Satisfaction with Psychiatry Care Questionnaire-22 was administered to 125 consecutive inpatients with schizophrenia or schizoaffective disorder in a stable condition. Read More

View Article
December 2018
5 Reads

The interactive effect of autism and psychosis severity on theory of mind and functioning in schizophrenia.

Neuropsychology 2018 Oct 22. Epub 2018 Oct 22.

Institute of Psychology, University of Lausanne.

Objective: Autism and schizophrenia are characterized by impairments in social cognition and functioning. They can co-occur at both the trait/symptom and diagnostic levels. We investigated the concurrent effect of autism and psychotic symptom severity on social cognition and functioning in schizophrenia. Read More

View Article
October 2018
1 Read

Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec.

Ther Adv Psychopharmacol 2018 Nov 22;8(11):287-301. Epub 2018 Jun 22.

CR-CHUM, University of Montréal, Montréal, Québec, Canada Faculty of Pharmacy, University of Montréal, Montréal, Québec, Canada.

Background: Long-acting injectable antipsychotics (LAI-AP) for patients with schizophrenia (SCZ) have saved significant healthcare costs. However, the cost effectiveness of LAI-AP for patients with other mental disorders has yet to be established. The goal of this study was to evaluate the impact of early initiation of LAI-AP medications on healthcare resource utilization (HRU). Read More

View Article
November 2018
3 Reads

A nationwide study on concordance with multimodal treatment guidelines in bipolar disorder.

Int J Bipolar Disord 2018 Oct 20;6(1):22. Epub 2018 Oct 20.

Altrecht Institute for Mental Health Care, Utrecht, Nieuwe Houtenseweg 12, 3524 SH, Utrecht, The Netherlands.

Background: Most previous studies on concordance with treatment guidelines for bipolar disorder focused on pharmacotherapy. Few studies have included other treatment modalities.

Aims: To study concordance with the Dutch guideline of various treatment modalities in outpatient treatment settings for patients with bipolar disorder and to identity factors associated with concordance. Read More

View Article
October 2018
8 Reads

Excited catatonia in a patient with fatal pulmonary embolism and a successful treatment strategy.

BMC Psychiatry 2018 Oct 19;18(1):342. Epub 2018 Oct 19.

Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, No. 123, Dapi Road, Niaosong District, Kaohsiung City, 833, Taiwan.

Background: Patients with psychiatric disorders in critical condition are difficult to treat. In this study, we report on a patient with underlying schizoaffective disorder who developed catatonia, cardiac arrest, and pulmonary embolism, as well as a successful treatment strategy.

Case Presentation: The inpatient is a 41-year-old morbidly obese male with schizoaffective disorder whose clozapine dosage was titrated from 100 mg to 175 mg due to auditory hallucination and agitation. Read More

View Article
October 2018
5 Reads

Cognitive Remediation Interventions in Schizoaffective Disorder: A Systematic Review.

Front Psychiatry 2018 4;9:470. Epub 2018 Oct 4.

Barcelona Bipolar Disorders Program, Institute of Neurosciences, IDIBAPS, CIBERSAM, Hospital Clinic, University of Barcelona, Barcelona, Spain.

Patients with schizoaffective disorder (SAD) suffer from cognitive impairment, which negatively influences their functionality. Cognitive remediation (CR) interventions have been shown to be effective in patients with schizophrenia (SZ) and bipolar disorder (BD), but evidence in SAD is limited so far. The aim of this study is to systematically review the published data on CR interventions, either in neurocognition or social cognition, in patients with SAD. Read More

View Article
October 2018
7 Reads

DISC1 gene polymorphisms and the risk of schizophrenia in an Iranian population: A preliminary study.

J Cell Biochem 2018 Oct 15. Epub 2018 Oct 15.

Department of Medical Microbiology, Microbiology Laboratory Lister, Tehran, Iran.

Background: Schizophrenia, schizoaffective disorder, and bipolar illness are common psychological disorders with high heritability and variable phenotypes. The disrupted in schizophrenia 1 ( DISC1) gene, on chromosome 1q42, has an essential role in neurite outgrowth and cell signaling. The purpose of this study was to investigate the association of three single-nucleotide polymorphisms (SNPs; rs6675281, rs2255340, and rs2738864) with schizophrenia disorder. Read More

View Article
October 2018
7 Reads

Metacognitive Deficits Predict Impaired Insight in Schizophrenia Across Symptom Profiles: A Latent Class Analysis.

Schizophr Bull 2019 Jan;45(1):48-56

Department of Psychology, Bar Ilan University, Ramat Gan, Israel.

The integrated model of insight in schizophrenia suggests that poor insight is the result of multiple factors which compromise persons' abilities to integrate streams of information into a personal awareness of psychiatric challenges, and make adaptive responses. This model hypothesizes that metacognitive deficits, or difficulties forming a complex and integrated understanding of the self and others, influence insight, regardless of other proximal causes including clinical profile. To explore this possibility, we performed a latent class analysis on 324 adults with schizophrenia or schizoaffective disorder. Read More

View Article
January 2019
3 Reads